Coexistence of Essential Thrombocythemia and Pituitary Adenoma: A Case Report of a Saudi Female Patient

Author:

Al-Ansari Rehab Yusuf1,Al Otaibi Maha Jurais2,Al-Ghamdi Amal Mohsen2,Al-Zahrani Nada Rajab3,Woodman Alexander4

Affiliation:

1. Department of Internal Medicine, Adult Hematology Unit, King Fahd Military Medical Complex, Dhahran, Saudi Arabia

2. Department of Internal Medicine, King Fahd Military Medical Complex, Dhahran, Saudi Arabia

3. Department of Internal Medicine, General Medicine Unit, King Fahd Military Medical Complex, Dhahran, Saudi Arabia

4. Department of Public Health,School of Health Sciences, University of Salford, Manchester, UK

Abstract

Abstract: Essential thrombocythemia (ET) is a malignant hematological disease that has the ability to progress to acute leukemia or transform into other myeloproliferative neoplasms (MPNs). The coexistence of ET and other MPNs with pituitary adenoma (PA) is rare. There are no reports of cases of secretory PA of prolactin hormone in combination with ET. This case was reported in a young woman from Saudi Arabia who had the secretory PA present in combination with ET. The 20-year-old patient was treated for a micro-PA with hyperprolactinemia. The patient was referred to the hematological service for thrombocytosis. There was no history of thrombosis, cardiovascular risk factors, or constitutional symptoms. Laboratory tests showed that platelet levels consistently lagged from 700 × 103/µL to 1000 × 103/µL for 1 year. Hemoglobin 13 g/dL, white blood cells (WBCs) 6 × 103/µL, and normal WBC differential. The peripheral blood smear was inconclusive. A peripheral blood sample was sent for the cytogenetic study of myeloproliferative diseases, which came to be positive for c.1849G>T p.(V617F) mutation in the EXON 14 Janus kinase 2 (JAK2) gene. The patient was diagnosed with a MPN, ET with positive exon 14 JAK2, at low-risk category. Evidence suggests that MPNs in combination with endocrinological diseases are rare. However, there is a high incidence of MPN and unrelated tumors such as PA. Further research is recommended to thoroughly investigate endocrine tumors and look beyond secondary thrombocytosis that leads to thrombocythemia as in ET.

Publisher

Medknow

Reference18 articles.

1. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms:Document summary and in-depth discussion;Barbui;Blood Cancer J,2018

2. The Essential thrombocythemia in 2020:What we know and where we still have to dig deep;Accurso;Clin Med Insights Blood Disord,2020

3. Isolated ten-eleven translocation 2 positive in triple negative essential thrombocythemia:Case report and literature review;Al-Ansari;SAGE Open Med Case Rep,2021

4. How I treat essential thrombocythemia;Rumi;Blood,2016

5. Polycythemia vera and essential thrombocythemia:2017 update on diagnosis, risk-stratification, and management;Tefferi;Am J Hematol,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3